SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
DNA methylation
acute promyelocytic leukemia
disease monitoring
measurable residual disease
patient follow-up
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
03
2020
accepted:
22
05
2020
entrez:
23
7
2020
pubmed:
23
7
2020
medline:
23
7
2020
Statut:
epublish
Résumé
Acute promyelocytic leukemia (APL) is characterized by a unique chromosome translocation t(15;17)(q24;q21), which leads to the PML/RARA gene fusion formation. However, it is acknowledged that this rearrangement alone is not able to induce the whole leukemic phenotype. In addition, epigenetic processes, such as DNA methylation, may play a crucial role in leukemia pathogenesis. DNA methylation, catalyzed by DNA methyltransferases (DNMTs), involves the covalent transfer of a methyl group (-CH3) to the fifth carbon of the cytosine ring in the CpG dinucleotide and results in the formation of 5-methylcytosine (5-mC). The aberrant gene promoter methylation can be an alternative mechanism of tumor suppressor gene inactivation. Understanding cancer epigenetics and its pivotal role in oncogenesis, can offer us not only attractive targets for epigenetic treatment but can also provide powerful tools in monitoring the disease and estimating the prognosis. Several genes of interest, such as RARA, RARB, p15, p16, have been studied in APL and their methylation status was correlated with potential diagnostic and prognostic significance. In the present manuscript we comprehensively examine the current knowledge regarding DNA methylation in APL pathogenesis. We also discuss the perspectives of using the DNA methylation patterns as reliable biomarkers for measurable residual disease (MRD) monitoring and as a predictor of relapse. This work also highlights the possibility of detecting aberrant methylation profiles of circulating tumor DNA (ctDNA) through liquid biopsies, using the conventional methods, such as methylation-specific polymerase chain reaction (MS-PCR), sequencing methods, but also revolutionary methods, such as surface-enhanced Raman spectroscopy (SERS).
Identifiants
pubmed: 32695677
doi: 10.3389/fonc.2020.01024
pmc: PMC7336895
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1024Informations de copyright
Copyright © 2020 Turcas, Moisoiu, Stefancu, Jurj, Iancu, Teodorescu, Pasca, Bojan, Trifa, Iluta, Zimta, Petrushev, Zdrenghea, Bumbea, Coriu, Dima, Leopold and Tomuleasa.
Références
J Cell Biochem. 2008 Aug 15;104(6):2059-70
pubmed: 18613031
Blood. 2010 Oct 28;116(17):3171-9
pubmed: 20644121
Br J Cancer. 2011 Feb 15;104(4):554-8
pubmed: 21245861
Nat Rev Genet. 2002 Nov;3(11):889-95
pubmed: 12415319
J Clin Pathol. 2014 Jul;67(7):626-31
pubmed: 24811488
Hum Pathol. 2019 Sep;91:1-10
pubmed: 31125631
Nat Commun. 2018 Dec 4;9(1):4915
pubmed: 30514834
Ann N Y Acad Sci. 2002 Dec;981:7-49
pubmed: 12547672
Cancer Cell. 2014 Apr 14;25(4):442-54
pubmed: 24656771
Blood. 2015 Jan 22;125(4):629-38
pubmed: 25416277
Sci Rep. 2019 May 7;9(1):7014
pubmed: 31065074
Sci Rep. 2019 Jul 1;9(1):9414
pubmed: 31263158
Haematologica. 2015 Aug;100(8):1064-75
pubmed: 26088929
Cold Spring Harb Perspect Biol. 2010 May;2(5):a000661
pubmed: 20452955
J Exp Med. 2016 Apr 4;213(4):483-97
pubmed: 26951332
Am J Hum Genet. 2017 Dec 7;101(6):888-902
pubmed: 29198723
JCI Insight. 2020 Jan 16;5(1):
pubmed: 31941838
Exp Hematol. 2017 Oct;54:17-25
pubmed: 28754309
Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1400-5
pubmed: 16432238
Cancer Cell. 2017 Nov 13;32(5):552-560
pubmed: 29136503
JAMA Oncol. 2018 Aug 1;4(8):1106-1110
pubmed: 29346478
Cell. 2002 Jan 25;108(2):165-70
pubmed: 11832207
Semin Cell Dev Biol. 2012 Jun;23(4):370-80
pubmed: 22306135
Mutat Res. 1993 Jan;285(1):61-7
pubmed: 7678134
Nanomedicine. 2019 Nov;22:102100
pubmed: 31648038
Science. 2017 May 5;356(6337):
pubmed: 28473536
Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5626-31
pubmed: 21427231
Nat Rev Mol Cell Biol. 2019 Oct;20(10):590-607
pubmed: 31399642
Biology (Basel). 2016 Jan 06;5(1):
pubmed: 26751487
Blood. 2019 Mar 28;133(13):1495-1506
pubmed: 30674471
Leukemia. 2005 Dec;19(12):2241-6
pubmed: 16239915
Leukemia. 2003 May;17(5):919-24
pubmed: 12750706
Science. 1975 Jan 24;187(4173):226-32
pubmed: 1111098
Cell Mol Life Sci. 2018 Jun;75(11):1999-2009
pubmed: 29484447
BMC Cancer. 2019 Jun 13;19(1):579
pubmed: 31195991
Ann N Y Acad Sci. 2002 Dec;981:61-81
pubmed: 12547674
Leukemia. 2002 Oct;16(10):1896-905
pubmed: 12357341
Int J Nanomedicine. 2019 Aug 02;14:6165-6178
pubmed: 31447558
Cancer Cell. 2017 May 8;31(5):612-613
pubmed: 28486101
Ann Oncol. 2016 Apr;27(4):599-608
pubmed: 27005468
Front Oncol. 2019 Jul 23;9:655
pubmed: 31396481
Nature. 2010 Dec 9;468(7325):839-43
pubmed: 21057493
J Gastrointestin Liver Dis. 2017 Mar;26(1):45-50
pubmed: 28338113
Oncotarget. 2018 Aug 31;9(68):32885-32899
pubmed: 30250637
Cancer Res. 2007 Feb 1;67(3):1370-7
pubmed: 17283175
Science. 2002 Feb 8;295(5557):1079-82
pubmed: 11834837
Cancer Cell. 2010 Dec 14;18(6):553-67
pubmed: 21130701
Cancer Res. 2010 Nov 1;70(21):8792-801
pubmed: 20861188
Genome Biol. 2016 Dec 12;17(1):255
pubmed: 27955697
Cancers (Basel). 2019 Oct 18;11(10):
pubmed: 31635329
Genes Dev. 2015 May 1;29(9):910-22
pubmed: 25886910
Blood. 2013 Jan 3;121(1):178-87
pubmed: 23152544
Hist Philos Life Sci. 2018 Sep 27;40(4):61
pubmed: 30264379
Genes Cancer. 2011 Feb;2(2):160-5
pubmed: 21779489
Cancer Cell. 2016 Jun 13;29(6):922-934
pubmed: 27300438
Genes Dev. 2016 Apr 1;30(7):733-50
pubmed: 27036965
Science. 2010 May 14;328(5980):916-9
pubmed: 20395474
Cytokine. 2011 Apr;54(1):6-19
pubmed: 21257317
Anal Bioanal Chem. 2015 May;407(12):3271-5
pubmed: 25791298
Semin Hematol. 2018 Jan;55(1):38-40
pubmed: 29759151
J Oncol. 2019 Dec 31;2019:5415761
pubmed: 32082377
Blood. 1998 Apr 15;91(8):2631-3
pubmed: 9531569
Nat Genet. 2016 Sep;48(9):1014-23
pubmed: 27428748
Stem Cells. 2012 Jan;30(1):89-93
pubmed: 22045578
Anal Bioanal Chem. 2019 Nov;411(29):7907-7913
pubmed: 31745615
Curr Biol. 2008 Mar 11;18(5):R191-2
pubmed: 18334189
J Clin Oncol. 2001 Apr 1;19(7):2033-40
pubmed: 11283136
Cancer Cell. 2010 Feb 17;17(2):173-85
pubmed: 20159609
Trends Mol Med. 2019 Nov;25(11):955-966
pubmed: 31253589
Nature. 2011 Dec 14;480(7378):490-5
pubmed: 22170606
Br J Haematol. 2003 Aug;122(4):571-8
pubmed: 12899712
Cancer Cell. 2017 May 8;31(5):697-710.e7
pubmed: 28486108
N Engl J Med. 2018 Jun 21;378(25):2386-2398
pubmed: 29860938
Cancer Cell. 2010 Feb 17;17(2):112-4
pubmed: 20159604
PLoS One. 2015 Jun 05;10(6):e0127790
pubmed: 26047326
Crit Rev Clin Lab Sci. 2018 Nov;55(7):501-515
pubmed: 30238808
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16121-6
pubmed: 24043786
Methods Mol Biol. 2012;889:385-406
pubmed: 22669678
J Clin Invest. 2016 Jan;126(1):85-98
pubmed: 26595813
Lancet Respir Med. 2018 May;6(5):379-388
pubmed: 29496485
Cancer Res Treat. 2017 Jul;49(3):790-797
pubmed: 28052659
Front Genet. 2019 Mar 01;10:133
pubmed: 30881380
Cancers (Basel). 2019 Dec 01;11(12):
pubmed: 31805753
Cell. 2017 Feb 23;168(5):801-816.e13
pubmed: 28215704